Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1-(4-Nitrophenyl)piperazine is an organic compound that serves as a valuable synthetic intermediate in the pharmaceutical industry. It is characterized by its molecular structure, which consists of a piperazine ring attached to a 4-nitrophenyl group. This unique structure endows it with specific chemical properties that make it suitable for various applications.

6269-89-2 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 6269-89-2 Structure
  • Basic information

    1. Product Name: 1-(4-Nitrophenyl)piperazine
    2. Synonyms: AKOS BBS-00003599;1-(P-NITROPHENYL)PIPERAZINE;1-NITRO-4-(1-PIPERAZINYL)BENZENE;1-(4-NITROPHENYL)PIPERAZINE;1-(4-NITRO-PHENYL)-PIPERAZINE DIHYDROCHLORIDE;1-(4-NITROPHENYL)PIPERAZINE HCL;LABOTEST-BB LT00076049;1-(4-Nitrophenyl)piperazine 97%
    3. CAS NO:6269-89-2
    4. Molecular Formula: C10H13N3O2
    5. Molecular Weight: 207.23
    6. EINECS: 228-443-7
    7. Product Categories: Nitrogen cyclic compounds;Piperidines, Piperidones, Piperazines;pharmacetical;Phenyls & Phenyl-Het;Piperaizine;API intermediates;CHIRAL CHEMICALS;Phenyls & Phenyl-Het;Building Blocks;Heterocyclic Building Blocks;Piperazines
    8. Mol File: 6269-89-2.mol
  • Chemical Properties

    1. Melting Point: 131-133 °C(lit.)
    2. Boiling Point: 346.25°C (rough estimate)
    3. Flash Point: 190.8 °C
    4. Appearance: White to beige to gray/Crystalline Powder, Crystals and/or Chunks
    5. Density: 1.1933 (rough estimate)
    6. Vapor Pressure: 2.38E-06mmHg at 25°C
    7. Refractive Index: 1.4830 (estimate)
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. PKA: 8.68±0.10(Predicted)
    11. CAS DataBase Reference: 1-(4-Nitrophenyl)piperazine(CAS DataBase Reference)
    12. NIST Chemistry Reference: 1-(4-Nitrophenyl)piperazine(6269-89-2)
    13. EPA Substance Registry System: 1-(4-Nitrophenyl)piperazine(6269-89-2)
  • Safety Data

    1. Hazard Codes: Xn,Xi
    2. Statements: 20/21/22-36/37/38
    3. Safety Statements: 26-37/39-24/25-36
    4. RIDADR: 2811
    5. WGK Germany: 3
    6. RTECS:
    7. HazardClass: 6.1
    8. PackingGroup: III
    9. Hazardous Substances Data: 6269-89-2(Hazardous Substances Data)

6269-89-2 Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Nitrophenyl)piperazine is used as a synthetic intermediate for the production of Itraconazole (I937500), an orally active antimycotic drug. It is structurally related to Ketoconazole and exhibits potent antifungal properties, making it an essential component in the development of effective antifungal medications.
As a synthetic intermediate, 1-(4-Nitrophenyl)piperazine plays a crucial role in the synthesis of Itraconazole, which is a widely used antifungal agent. Its ability to inhibit the growth of various fungi, including Candida and Aspergillus species, makes it a valuable asset in the treatment of fungal infections. Furthermore, its oral administration and broad-spectrum antifungal activity contribute to its widespread use in the pharmaceutical industry.

Check Digit Verification of cas no

The CAS Registry Mumber 6269-89-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,2,6 and 9 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 6269-89:
(6*6)+(5*2)+(4*6)+(3*9)+(2*8)+(1*9)=122
122 % 10 = 2
So 6269-89-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H13N3O2/c14-13(15)10-3-1-9(2-4-10)12-7-5-11-6-8-12/h1-4,11H,5-8H2/p+1

6269-89-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (L18700)  1-(4-Nitrophenyl)piperazine, 98+%   

  • 6269-89-2

  • 5g

  • 266.0CNY

  • Detail
  • Alfa Aesar

  • (L18700)  1-(4-Nitrophenyl)piperazine, 98+%   

  • 6269-89-2

  • 25g

  • 856.0CNY

  • Detail
  • Alfa Aesar

  • (L18700)  1-(4-Nitrophenyl)piperazine, 98+%   

  • 6269-89-2

  • 100g

  • 3057.0CNY

  • Detail
  • Aldrich

  • (279773)  1-(4-Nitrophenyl)piperazine  97%

  • 6269-89-2

  • 279773-5G

  • 457.47CNY

  • Detail

6269-89-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(4-Nitrophenyl)piperazine

1.2 Other means of identification

Product number -
Other names 1-Nitro-4-piperazinobenzene

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6269-89-2 SDS

6269-89-2Synthetic route

tert-butyl 4-(4-nitrophenyl)piperazine-1-carboxylate
182618-86-6

tert-butyl 4-(4-nitrophenyl)piperazine-1-carboxylate

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 6h;98%
Stage #1: tert-butyl 4-(4-nitrophenyl)piperazine-1-carboxylate With Amberlyst(R) 15 In dichloromethane at 20℃;
Stage #2: With ammonium hydroxide In methanol at 20℃; for 1.5h;
94%
With trifluoroacetic acid In dichloromethane at 20℃; for 1h;90%
piperazine
110-85-0

piperazine

para-nitrophenyl bromide
586-78-7

para-nitrophenyl bromide

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Conditions
ConditionsYield
With tetra-(n-butyl)ammonium iodide; potassium carbonate In dimethyl sulfoxide at 120℃; for 12h; Arylation;98%
With potassium carbonate In N,N-dimethyl-formamide Reflux;55%
With potassium phosphate; copper(l) iodide; ethylene glycol In isopropyl alcohol for 48h; Heating / reflux;49.4%
piperazine
110-85-0

piperazine

4-Fluoronitrobenzene
350-46-9

4-Fluoronitrobenzene

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Conditions
ConditionsYield
In N,N-dimethyl-formamide under 6000.6 Torr;95%
In acetonitrile Reflux;85.1%
In chloroform; acetonitrile
piperazine
110-85-0

piperazine

4-chlorobenzonitrile
100-00-5

4-chlorobenzonitrile

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Conditions
ConditionsYield
With tetra-(n-butyl)ammonium iodide; potassium carbonate In dimethyl sulfoxide at 120℃; for 12h; Arylation;91%
With tris-(dibenzylideneacetone)dipalladium(0); 2-dicyclohexylphosphino-2′,6′-di-i-propoxy-1,1′-biphenyl; sodium t-butanolate In 1,4-dioxane at 100℃; for 0.166667h; Temperature;86%
In diethylene glycol dimethyl ether at 100℃; for 6h;81%
bis-(2-chloroethyl)amine hydrochloride
821-48-7

bis-(2-chloroethyl)amine hydrochloride

4-nitro-aniline
100-01-6

4-nitro-aniline

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Conditions
ConditionsYield
In various solvent(s) at 150℃;90%
With potassium carbonate In butan-1-ol16.1 g (14%)
Reflux;
With potassium iodide at 150℃; Inert atmosphere;
piperazine
110-85-0

piperazine

para-dinitrobenzene
100-25-4

para-dinitrobenzene

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Conditions
ConditionsYield
With potassium carbonate In dimethyl sulfoxide Arylation; Heating;76%
bis(2-bromoethyl)amine hydrobromide
43204-63-3

bis(2-bromoethyl)amine hydrobromide

4-nitro-aniline
100-01-6

4-nitro-aniline

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Conditions
ConditionsYield
With butan-1-ol
piperazine
110-85-0

piperazine

4-chlorobenzonitrile
100-00-5

4-chlorobenzonitrile

A

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

B

N.N'-bis-<4-nitro-phenyl>-piperazine

N.N'-bis-<4-nitro-phenyl>-piperazine

Conditions
ConditionsYield
at 150℃; im Rohr;
piperazine
110-85-0

piperazine

p-nitrobenzene iodide
636-98-6

p-nitrobenzene iodide

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Conditions
ConditionsYield
With potassium phosphate; copper(l) iodide In isopropyl alcohol at 20℃;
4-Fluoronitrobenzene
350-46-9

4-Fluoronitrobenzene

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: macroporous polymer-supported carbonate / dimethylsulfoxide / 100 °C
1.2: macroporous polymer-supported isocyanate / CH2Cl2 / 60 °C
2.1: Amberlyst(R) 15 / CH2Cl2 / 20 °C
2.2: 94 percent / aq. NH3 / methanol / 1.5 h / 20 °C
View Scheme
Multi-step reaction with 2 steps
1: K2CO3 / dimethylsulfoxide / 12 h / 80 °C
2: concd. HCl / acetonitrile
View Scheme
Multi-step reaction with 2 steps
1: potassium carbonate / acetonitrile / 48 h / Reflux
2: hydrogenchloride; acetic acid / water / 2 h / 20 °C
View Scheme
para-nitrophenyl bromide
586-78-7

para-nitrophenyl bromide

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: tri-tert-butylphosphine; palladium(II) acetate; sodium tert-butoxide / xylene / 50 °C
1.2: 100 percent / macroporous polymer-supported isocyanate / xylene / 24 h / 50 °C
2.1: Amberlyst(R) 15 / CH2Cl2 / 20 °C
2.2: 94 percent / aq. NH3 / methanol / 1.5 h / 20 °C
View Scheme
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

4-(piperazin-1-yl)aniline
67455-41-8

4-(piperazin-1-yl)aniline

Conditions
ConditionsYield
With hydrazine hydrate at 90℃; for 1.66667h; chemoselective reaction;100%
With palladium 10% on activated carbon In methanol at 50℃; under 37503.8 Torr;99%
With hydrazine hydrate In water at 110℃; Sealed tube; Green chemistry;99%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

3,4-dimethoxy-benzaldehyde
120-14-9

3,4-dimethoxy-benzaldehyde

1-(3,4-dimethoxybenzyl)-4-(4-nitrophenyl)piperazine
414877-58-0

1-(3,4-dimethoxybenzyl)-4-(4-nitrophenyl)piperazine

Conditions
ConditionsYield
With sodium tris(acetoxy)borohydride In dichloromethane for 18h;100%
Stage #1: 1-(4-Nitrophenyl)piperazine; 3,4-dimethoxy-benzaldehyde With acetic acid In dichloromethane for 0.5h;
Stage #2: With sodium tris(acetoxy)borohydride In dichloromethane at 20℃;
60.9%
[(1-Ethoxycyclopropyl)oxy]trimethylsilane
27374-25-0

[(1-Ethoxycyclopropyl)oxy]trimethylsilane

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

1-cyclopropyl-4-(4-nitrophenyl)piperazine
700804-16-6

1-cyclopropyl-4-(4-nitrophenyl)piperazine

Conditions
ConditionsYield
With sodium cyanoborohydride; acetic acid In methanol at 20℃; for 60h; molecular sieves;100%
With sodium cyanoborohydride; acetic acid In methanol at 60 - 65℃; for 4h; Molecular sieve;100%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

isobutyl isocyanate
1873-29-6

isobutyl isocyanate

4-(4-nitrophenyl)-1-piperazinecarbothioic acid isobutylamide
412332-12-8

4-(4-nitrophenyl)-1-piperazinecarbothioic acid isobutylamide

Conditions
ConditionsYield
In toluene at 20℃; for 2h;100%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

Ethanesulfonyl chloride
594-44-5

Ethanesulfonyl chloride

1-(ethylsulfonyl)-4-(4-nitrophenyl)piperazine
544462-63-7

1-(ethylsulfonyl)-4-(4-nitrophenyl)piperazine

Conditions
ConditionsYield
With triethylamine In dichloromethane at 5 - 20℃; for 4h;100%
With triethylamine In dichloromethane at 5 - 20℃; for 4h;100%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

2-chloro-5-cyano-6-ethoxy-4-phenylpyridine-3-carboxaldehyde
143815-60-5

2-chloro-5-cyano-6-ethoxy-4-phenylpyridine-3-carboxaldehyde

3-cyano-2-ethoxy-6--5-formyl-4-phenylpyridine
151021-19-1

3-cyano-2-ethoxy-6--5-formyl-4-phenylpyridine

Conditions
ConditionsYield
With triethylamine In tetrahydrofuran for 0.166667h; Heating;99%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

4-nitrobenzyl chloride
100-14-1

4-nitrobenzyl chloride

1-(4-nitro-benzyl)-4-(4-nitro-phenyl)-piperazine

1-(4-nitro-benzyl)-4-(4-nitro-phenyl)-piperazine

Conditions
ConditionsYield
With silica gel for 0.0833333h; Alkylation; Microwave irradiation;99%
potassium cyanate
590-28-3

potassium cyanate

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

4-(4-nitro-phenyl)-piperazine-1-carboxylic acid amide
63178-62-1

4-(4-nitro-phenyl)-piperazine-1-carboxylic acid amide

Conditions
ConditionsYield
99%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

ethyl bromoacetate
105-36-2

ethyl bromoacetate

ethyl 2-[4-(4-nitrophenyl)piperazin-1-yl]acetate
24636-99-5

ethyl 2-[4-(4-nitrophenyl)piperazin-1-yl]acetate

Conditions
ConditionsYield
With triethylamine In neat (no solvent) for 0.133333h; Solvent; Microwave irradiation; Green chemistry;99%
With sodium hydrogencarbonate In acetone for 24h; Reflux;
With potassium carbonate In acetone at 20℃;
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

N-(4-methylphenyl)-4-nitronaphthalene-1,8-dicarboximide
129-23-7

N-(4-methylphenyl)-4-nitronaphthalene-1,8-dicarboximide

6-[4-(4-nitro-phenyl)-piperazin-1-yl]-2-p-tolyl-benzo[de]isoquinoline-1,3-dione

6-[4-(4-nitro-phenyl)-piperazin-1-yl]-2-p-tolyl-benzo[de]isoquinoline-1,3-dione

Conditions
ConditionsYield
In N,N-dimethyl acetamide for 3h; Heating;98%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

(R)-trolox
53101-49-8

(R)-trolox

(R)-3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-nitrophenyl)-1-piperazinyl]-carbonyl}-2H-1-benzopyran-6-ol

(R)-3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-nitrophenyl)-1-piperazinyl]-carbonyl}-2H-1-benzopyran-6-ol

Conditions
ConditionsYield
Stage #1: (R)-trolox
Stage #2: 1-(4-Nitrophenyl)piperazine
98%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide
82911-69-1

N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide

4-(4-nitrophenyl)piperazine-1-N-9H-fluoren-9-ylmethyloxycarbonyl

4-(4-nitrophenyl)piperazine-1-N-9H-fluoren-9-ylmethyloxycarbonyl

Conditions
ConditionsYield
With sodium carbonate In DMF (N,N-dimethyl-formamide); water at 0℃; for 0.333333h;98%
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

tert-butyl 4-(4-dimethylaminophenyl)piperazine-1-carboxylate

tert-butyl 4-(4-dimethylaminophenyl)piperazine-1-carboxylate

Conditions
ConditionsYield
With formaldehyd; palladium In ethanol; dichloromethane; ethyl acetate98%
(1S,4R)-bicyclo[2.2.1]heptan-2-one
497-38-1, 2630-41-3

(1S,4R)-bicyclo[2.2.1]heptan-2-one

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

1-(bicyclo[2.2.1]hept-2-yl)-4-(4-nitrophenyl)piperazine
1037800-79-5

1-(bicyclo[2.2.1]hept-2-yl)-4-(4-nitrophenyl)piperazine

Conditions
ConditionsYield
With sodium tris(acetoxy)borohydride; acetic acid In 1,2-dichloro-ethane at 20℃;98%
2-chloro-4,6-dimethoxybenzenamine hydrochloride
1092069-98-1

2-chloro-4,6-dimethoxybenzenamine hydrochloride

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

trichloromethyl chloroformate
503-38-8

trichloromethyl chloroformate

C19H21ClN4O5
1092069-29-8

C19H21ClN4O5

Conditions
ConditionsYield
Stage #1: 2-chloro-4,6-dimethoxybenzenamine hydrochloride; trichloromethyl chloroformate With triethylamine In toluene at 60℃; for 2h;
Stage #2: 1-(4-Nitrophenyl)piperazine In dichloromethane; toluene at 60 - 70℃; for 1h;
98%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

4-methoxy-benzoyl chloride
100-07-2

4-methoxy-benzoyl chloride

1-(4-methoxybenzoyl)-4-(4-nitrophenyl)piperazine

1-(4-methoxybenzoyl)-4-(4-nitrophenyl)piperazine

Conditions
ConditionsYield
With triethylamine In tetrahydrofuran at 0 - 20℃; for 4h;98%
With triethylamine In dichloromethane at 20℃;88%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

2-bromoethanol
540-51-2

2-bromoethanol

2-(4-(4-nitrophenyl)piperazin-1-yl)ethan-1-ol
5521-38-0

2-(4-(4-nitrophenyl)piperazin-1-yl)ethan-1-ol

Conditions
ConditionsYield
With triethylamine In chloroform at 50℃;97%
With triethylamine In acetone at 20℃; for 24h;40%
With N-ethyl-N,N-diisopropylamine In acetonitrile Heating / reflux;
With N-ethyl-N,N-diisopropylamine In acetonitrile Heating / reflux;
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

N-(5-chloro-2-nitrophenyl)acetamide
5443-33-4

N-(5-chloro-2-nitrophenyl)acetamide

5-(4-(4-nitrophenyl)-1-piperazinyl)-2'-nitroacetanilide
1612254-27-9

5-(4-(4-nitrophenyl)-1-piperazinyl)-2'-nitroacetanilide

Conditions
ConditionsYield
With triethylamine In dimethyl sulfoxide at 120℃;97%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

methyl chloroformate
79-22-1

methyl chloroformate

methyl 4-(4-nitrophenyl)piperazine-1-carboxylate
91643-97-9

methyl 4-(4-nitrophenyl)piperazine-1-carboxylate

Conditions
ConditionsYield
With potassium carbonate In dichloromethane at 20℃; for 0.5h;97%
With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 0 - 20℃; for 1h;4 g
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

benzyl chloroformate
501-53-1

benzyl chloroformate

benzyl 4-(4-nitropheny)piperazine-1-carboxylate
947673-13-4

benzyl 4-(4-nitropheny)piperazine-1-carboxylate

Conditions
ConditionsYield
With potassium carbonate In tetrahydrofuran; water for 1h; Inert atmosphere;96.4%
With sodium hydrogencarbonate In dichloromethane; acetonitrile at 8 - 20℃; for 40h;96%
With sodium hydrogencarbonate In dichloromethane for 21h;93%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

3-[(4-chlorobenzoyl)amino]propanoyl chloride
755024-79-4

3-[(4-chlorobenzoyl)amino]propanoyl chloride

4-chloro-N-[3-oxo-3-(4-(4-nitrophenyl)-1-piperazinyl)-propyl]-benzamide

4-chloro-N-[3-oxo-3-(4-(4-nitrophenyl)-1-piperazinyl)-propyl]-benzamide

Conditions
ConditionsYield
With pyridine In tetrahydrofuran at 0 - 20℃;96.2%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

3-(Trifluoromethyl)benzenesulfonyl chloride
777-44-6

3-(Trifluoromethyl)benzenesulfonyl chloride

1-(4-nitro-phenyl)-4-(3-trifluoromethyl-benzenesulfonyl)-piperazine

1-(4-nitro-phenyl)-4-(3-trifluoromethyl-benzenesulfonyl)-piperazine

Conditions
ConditionsYield
With silica gel for 0.0833333h; Substitution; Microwave irradiation;96%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

acrylonitrile
107-13-1

acrylonitrile

3-[4-(4-nitrophenyl)-piperazin-1-yl]-propionitrile
743449-17-4

3-[4-(4-nitrophenyl)-piperazin-1-yl]-propionitrile

Conditions
ConditionsYield
With triethylammonium acetate at 25℃; for 0.0166667h; Aza-Michael reaction; chemoselective reaction;96%
With multi-walled carbon nanotubes-triethylammonium hydrogen phosphate composite at 25℃; for 0.0166667h; Michael Addition; Green chemistry;96%
With triethylamine In methanol at 20℃; for 24h;91.04%
With single-walled carbon nanotube-triethylammonium hydrogen phosphate ionic liquid at 25℃; for 0.0166667h; Reagent/catalyst;97 %Chromat.
dichloroacethyl chloride
79-36-7

dichloroacethyl chloride

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

2,2-dichloro-1-(4-(4-nitrophenyl)piperazine-1-yl)ethan-1-one
77367-94-3

2,2-dichloro-1-(4-(4-nitrophenyl)piperazine-1-yl)ethan-1-one

Conditions
ConditionsYield
for 4h;96%
With triethylamine In water; toluene
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

propargyl bromide
106-96-7

propargyl bromide

N-(4-nitrophenyl)-N'-propargylpiperazine
72955-80-7

N-(4-nitrophenyl)-N'-propargylpiperazine

Conditions
ConditionsYield
With potassium carbonate In acetonitrile at 60℃; for 18h; Inert atmosphere;95.4%
With pyridine; potassium carbonate In ethyl acetate at 25℃; for 4h; Cooling with ice;
With potassium carbonate In ethyl acetate at 20℃;
With potassium carbonate In dichloromethane at 0 - 20℃; for 5h;
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

chloroacetyl chloride
79-04-9

chloroacetyl chloride

2-chloro-1-<4-(4-nitrophenyl)piperazin-1-yl>acetamide
16264-11-2

2-chloro-1-<4-(4-nitrophenyl)piperazin-1-yl>acetamide

Conditions
ConditionsYield
With calcium carbonate In butanone Ambient temperature;95%
With triethylamine In dichloromethane at 0 - 20℃; for 3h;92%
formaldehyd
50-00-0

formaldehyd

tetrahydropyrrolo[1,2-c]imidazol-1,3-dione
5768-79-6

tetrahydropyrrolo[1,2-c]imidazol-1,3-dione

1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

2-[4-(4-Nitro-phenyl)-piperazin-1-ylmethyl]-tetrahydro-pyrrolo[1,2-c]imidazole-1,3-dione

2-[4-(4-Nitro-phenyl)-piperazin-1-ylmethyl]-tetrahydro-pyrrolo[1,2-c]imidazole-1,3-dione

Conditions
ConditionsYield
In ethanol at 100℃;95%
1-(4-Nitrophenyl)piperazine
6269-89-2

1-(4-Nitrophenyl)piperazine

4-(4-nitrophenyl)piperazine-1-carbaldehyde
321898-63-9

4-(4-nitrophenyl)piperazine-1-carbaldehyde

Conditions
ConditionsYield
In acetonitrile for 7.5h; Formylation;95%

6269-89-2Relevant articles and documents

Methylene violet derivative fluorescent probe as well as synthesis method and application thereof

-

Paragraph 0052-0056, (2021/03/13)

The invention discloses a methylene violet derivative fluorescent probe as well as a synthesis method and application thereof. The fluorescent probe is connected with an NBD group through piperazine on the basis of a cationic main structure of methylene violet. The preparation method comprises the following steps: directly reacting methylene violet 3RAX with piperazine, or firstly reacting with X-R5-X and then reacting with piperazine, and finally introducing an NBD group to a piperazine group to obtain the target fluorescent probe; or reacting 4-fluoronitrobenzene, piperazine and aniline to obtain a cationic main structure of methylene violet, and finally introducing an NBD group to a piperazine group to obtain the target fluorescent probe. The fluorescent probe is good in water solubility, can be used for sulfur ion detection, is high in detection sensitivity and low in detection limit, and can also be used as a tumor photodynamic therapy probe to quickly release singlet oxygen for tumor photodynamic therapy; synthesis is simple, conditions are mild, and cost is low.

Synthesis and structure-activity relationships of new 2-phenoxybenzamides with antiplasmodial activity

Dolensky, Johanna,Hermann, Theresa,Hochegger, Patrick,Kaiser, Marcel,M?ser, Pascal,Pferschy-Wenzig, Eva-Maria,Saf, Robert,Seebacher, Werner,Weis, Robert

, (2021/11/08)

The 2-phenoxybenzamide 1 from the Medicines for Malaria Venture Malaria Box Project has shown promising multi-stage activity against different strains of P. falciparum. It was successfully synthesized via a retrosynthetic approach. Subsequently, twenty-one new derivatives were prepared and tested for their in vitro activity against blood stages of the NF54 strain of P. falciparum. Several insights into structure-activity relationships were revealed. The antiplasmodial activity and cytotoxicity of compounds strongly depended on the substitution pattern of the anilino partial structure as well as on the size of substituents. The diaryl ether partial structure had further impacts on the activity. Additionally, several physicochemical and pharmacokinetic parameters were calculated (log P, log D7.4 and ligand efficiency) or determined experimentally (passive permeability and CYP3A4 inhibition). The tert-butyl-4-{4-[2-(4-fluorophenoxy)-3-(trifluoromethyl)benzamido]phenyl}piperazine-1-carboxylate possesses high antiplasmodial activity against P. falciparum NF54 (PfNF54 IC50 = 0.2690 μM) and very low cytotoxicity (L-6 cells IC50 = 124.0 μM) resulting in an excellent selectivity index of 460. Compared to the lead structure 1 the antiplasmodial activity was improved as well as the physicochemical and some pharmacokinetic parameters.

Toll-like receptor-7 small molecule inhibitor and preparation method thereof

-

Paragraph 0147; 0150-0151, (2021/02/24)

The invention belongs to the field of chemical small molecules, and particularly relates to a Toll-like receptor-7 small molecule inhibitor. The invention provides the Toll-like receptor-7 small molecule inhibitor, which takes a co-inhibitor of TLR7 and TLR8 obtained by screening as a research object, realizes selective regulation and control of TLR7 and TLR8 through the research on the structureoptimization and structure-activity relationship (SAR) of a parent compound, and further develops a high-efficiency, non-toxic and specific small molecule inhibitor with certain selectivity on TLR 7.The TLR7 small molecule inhibitor has a certain effect and potential medicinal value in autoimmune diseases (systemic lupus erythematosus).

Five-membered heteroaromatic ring derivative as well as preparation method and application thereof

-

Paragraph 0134-0138, (2021/09/26)

The invention discloses a five-membered heteroaromatic ring derivative and a preparation method and application thereof, and the compound has obvious inhibition on DHODH. The blocking effect can be used as DHODH specific inhibitor, can be used for preparing medicines for treating diseases caused by fungal infection, can be used for preparing agricultural fungicides, and has wide application prospects.

WEE1 inhibitors as well as preparation and application thereof

-

Paragraph 0215-0221; 0411-0417, (2020/10/14)

The invention relates to WEE1 inhibitors as well as preparation and application thereof. The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates, polymorphs or isomers thereof, and their use in the preparation of medicaments for the treatment of diseases associated with WEE1 activity.

Discovery and SARs of 5-Chloro- N4-phenyl- N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Wang, Yang,Chen, Xing,Yan, Yaoyao,Zhu, Xiaochen,Liu, Mingming,Liu, Xinhua

, p. 3327 - 3347 (2020/04/08)

Cyclin-dependent kinases (CDKs) are promising therapeutic targets for cancer therapy. Herein, we describe our efforts toward the discovery of a series of 5-chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as dual CDK6 and 9 inhibitors. Intensive structural modifications lead to the identification of compound 66 as the most active dual CDK6/9 inhibitor with balancing potency against these two targets and good selectivity over CDK2. Further biological studies revealed that compound 66 was directly bound to CDK6/9, resulting in suppression of their downstream signaling pathway and inhibition of cell proliferation by blocking cell cycle progression and inducing cellular apoptosis. More importantly, compound 66 significantly inhibited tumor growth in a xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment. Therefore, the above results are of great importance in the development of dual CDK6/9 inhibitors for cancer therapy.

Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents

Zhang, Li,Wu, Yuhang,Yang, Guixiang,Gan, Haixian,Sang, Dayong,Zhou, Jiye,Su, Lin,Wang, Rui,Ma, Lei

supporting information, (2020/11/03)

A total of 26 compounds based on osthole skeleton were designed, synthesized. Their cytoprotective abilities of antioxidation, anti-inflammation and Aβ42(Amyloid β-protein 42)-induced neurotoxicity were evaluated by MTT assays. Mechanism of the action of selected compounds were investigated by molecular docking. AlogP, logS and blood–brain barrier (BBB) permeability of all these compounds were simulated by admetSAR. Most of the compounds showed better antioxidative and anti-inflammatory activities compared with osthole, especially OST7 and OST17. The compound OST7 showed relative high activity in neuroprotection against H2O2 (45.7 ± 5.5%), oxygen glucose deprivation (64.6 ± 4.8%) and Aβ42 (61.4 ± 5.2%) at a low concentration of 10 μM. EC50 of selected compounds were measured in both H2O2 and OGD induced cytotoxicity models. Moreover, NO inhibiting ability of OST17(50.4 ± 7.1%) already surpassed the positive drug indomethacin. The structure activity relationship study indicated that introduction of piperazine group, tetrahydropyrrole group and aromatic amine group might be beneficial for enhancement of osthole neuroprotective properties. Molecular docking explained that the reason OST7 exhibited relatively stronger neuroprotection against Aβ because of the greater area of interactions between molecule and target protein. OST7 and OST17 both provided novel methods to investigate osthole as anti-AD drugs.

METHOD OF TREATING COCCIDIOIDES INFECTION

-

Paragraph 0200; 0213-0214, (2020/11/10)

The invention relates to the therapeutic use of olorofim, 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide in the prevention and treatment of a fungal infection caused by a Coccidioides species.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

-

Paragraph 0334-0336, (2019/04/25)

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

Phenylpiperazine type UBE2F small molecule inhibitor and synthesis method thereof

-

Paragraph 0034-0035; 0038-0039, (2019/09/14)

The invention discloses a phenylpiperazine type UBE2F small molecule inhibitor and a synthesis method thereof, discloses a phenylpiperazine type compound represented by the general formula I or a pharmaceutically acceptable salt thereof, and further discloses a synthesis route of the general formula I and a synthesis method of each step. As a small molecule inhibitor target at UBE2F, that phenylpiperazine type compound of the present invention effectively suppresses the growth of tumor cell by preventing the G2/M process of cell cycle and inducing apoptosis of human tumor cells. Therefore, thecompound is a new class of specific anti-tumor drugs by targeting UBE2F.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 6269-89-2